57 related articles for article (PubMed ID: 8509840)
1. Immunoadsorption: an enhancement strategy for radioimmunotherapy.
DeNardo GL; Maddock SW; Sgouros G; Scheibe PO; DeNardo SJ
J Nucl Med; 1993 Jun; 34(6):1020-7. PubMed ID: 8509840
[No Abstract] [Full Text] [Related]
2. Quality control of radiolabeled monoclonal antibodies.
Khazaeli MB
Cancer Biother Radiopharm; 2000 Dec; 15(6):529-30. PubMed ID: 11190485
[No Abstract] [Full Text] [Related]
3. Genetically engineered immunoconjugates: a dosimetric dilemma?
Perkins AC
Nucl Med Commun; 1993 Dec; 14(12):1047-9. PubMed ID: 8295759
[No Abstract] [Full Text] [Related]
4. A model for others: a strategy for improving diagnosis and therapy of human malignancies using monoclonal antibodies targeting TAG-72 oncofetal antigen.
Larson SM
Cancer Invest; 1993; 11(2):235-8. PubMed ID: 8462025
[No Abstract] [Full Text] [Related]
5. [Monoclonal antibodies. An approach to diagnosis and treatment of micrometastases].
Bier H
HNO; 1994 May; 42(5):255-6. PubMed ID: 8050912
[No Abstract] [Full Text] [Related]
6. Principles of radioimmunotherapy for hematologists and oncologists.
Press OW; Rasey J
Semin Oncol; 2000 Dec; 27(6 Suppl 12):62-73. PubMed ID: 11226002
[TBL] [Abstract][Full Text] [Related]
7. Improved tumor targeting by combined use of two antitenascin antibodies.
Petronzelli F; Pelliccia A; Anastasi AM; D'Alessio V; Albertoni C; Rosi A; Leoni B; De Angelis C; Paganelli G; Palombo G; Dani M; Carminati P; De Santis R
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7137s-7145s. PubMed ID: 16203813
[TBL] [Abstract][Full Text] [Related]
8. All of the above (with caveats for each).
Divgi CR
J Nucl Med; 1998 Jan; 39(1):42-3. PubMed ID: 9443736
[No Abstract] [Full Text] [Related]
9. Improving tumor-to-normal-tissue ratios of antibodies by extracorporeal immunoadsorption based on the avidin-biotin concept: development of a new treatment strategy applied to monoclonal antibodies murine L6 and chimeric BR96.
Tennvall J; Garkavij M; Chen J; Sjögren HO; Strand SE
Cancer; 1997 Dec; 80(12 Suppl):2411-8. PubMed ID: 9406691
[TBL] [Abstract][Full Text] [Related]
10. alpha-Particle emitters in radioimmunotherapy: new and welcome challenges to medical internal dosimetry.
Bolch WE
J Nucl Med; 2001 Aug; 42(8):1222-4. PubMed ID: 11483683
[No Abstract] [Full Text] [Related]
11. Two-step immunological approaches for imaging and therapy.
Rosebrough SF
Q J Nucl Med; 1996 Sep; 40(3):234-51. PubMed ID: 8961802
[TBL] [Abstract][Full Text] [Related]
12. Preface of the workshop on innovative personalized radioimmunotherapy (WIPR 2013).
Huclier S
Nucl Med Biol; 2014 May; 41 Suppl():e1-6. PubMed ID: 24759271
[No Abstract] [Full Text] [Related]
13. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate.
Berndorff D; Borkowski S; Sieger S; Rother A; Friebe M; Viti F; Hilger CS; Cyr JE; Dinkelborg LM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7053s-7063s. PubMed ID: 16203802
[TBL] [Abstract][Full Text] [Related]
14. Pretargeted radioimmunotherapy of cancer: progress step by step.
Boerman OC; van Schaijk FG; Oyen WJ; Corstens FH
J Nucl Med; 2003 Mar; 44(3):400-11. PubMed ID: 12621007
[TBL] [Abstract][Full Text] [Related]
15. Microscopic intratumoral dosimetry of radiolabeled antibodies is a critical determinant of successful radioimmunotherapy in B-cell lymphoma.
Du Y; Honeychurch J; Glennie M; Johnson P; Illidge T
Cancer Res; 2007 Feb; 67(3):1335-43. PubMed ID: 17283171
[TBL] [Abstract][Full Text] [Related]
16. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
[TBL] [Abstract][Full Text] [Related]
17. Implications of nonuniform tumor doses for radioimmunotherapy.
O'Donoghue JA
J Nucl Med; 1999 Aug; 40(8):1337-41. PubMed ID: 10450686
[TBL] [Abstract][Full Text] [Related]
18. Introduction to the Seventh Conference on Radioimmunodetection and Radioimmunodetection and Radioimmunotherapy of Cancer.
Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):2991s. PubMed ID: 10541331
[No Abstract] [Full Text] [Related]
19. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L
J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
